arrow
A

Adrian Bloor

University of Manchester
H指数:35
被引数:6,299

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party

纠正:基于体内T细胞清除(ATG与alemtuzumab)的GVHD预防方案比较,用于接受异基因造血干细胞移植的AML患者,移植预处理强度为中等强度方案:代表EBMT急性白血病工作组进行的登记研究

2026-10-230
OAAI
Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort—A study by the EBMT Lymphoma Working Party

自体干细胞移植在NK/T细胞淋巴瘤中的应用:EBV-DNA在跨国队列中的预后影响——EBMT淋巴瘤工作组的研究

2025-08-150
OAAI
Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT

不同初始干细胞移植策略治疗多发性骨髓瘤的结局:EBMT慢性恶性疾病工作组从统计学角度进行的分析

2025-07-300
OAAI
Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party

达鲁atumumab治疗造血干细胞移植后纯红细胞再生障碍:EBMT移植并发症工作组的研究与实践考量

2025-06-040
OAAI
Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

自体造血干细胞移植在自然杀伤/T细胞淋巴瘤中的应用:EBMT淋巴瘤工作组的一项回顾性分析

BLOOD
IF23.1
2024-11-050
PRE
Predictors of Successful Allogeneic Stem Cell Donor Collection

异基因干细胞供者采集成功的预测因素

BLOOD
IF23.1
2024-11-050
PRE
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
LEUKEMIA
IF13.4
2024-07-230
OAAI
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

以可测量的残留疾病为指导的慢性淋巴细胞白血病治疗

2024-01-2550
OA
Graft-versus-Host Disease Prophylaxis with PostTransplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)

在接受来自无关或不匹配的相关供体的异基因造血细胞移植的慢性粒细胞白血病患者中,移植后环磷酰胺预防移植物抗宿主病: 来自EBMT慢性恶性肿瘤工作组 (cmwp-ebmt) 的比较研究

2024-01-011
OAAI
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party

CD19 CAR T细胞治疗大b细胞淋巴瘤后的器官并发症: 来自EBMT移植并发症和淋巴瘤工作组的回顾性研究

2023-09-272
OAAI
Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

骨髓增殖性肿瘤原始细胞期患者异基因造血干细胞移植后的结果: 一项来自欧洲血液和骨髓移植学会慢性恶性肿瘤工作组的回顾性研究

2023-01-1313
OA
Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors
2022-02-121
OA
Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting
2021-11-099
OAAI
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
LEUKEMIA
IF13.4
2021-11-0882
OAAI